Resource News

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of innovative technologies and novel therapeutics targeting organ inflammation, announced that an ARCH scientist at the University of Calgary was awarded a Canadian Institute of Health Resources (CIHR) Project Grant worth $1,109,250 to further study the role of dipeptidase-1 (DPEP-1) in renal inflammation and chronic kidney disease (CKD).

The CIHR grant entitled "A Multifaceted Function for Dipeptidase-1 in Kidney Injury" was awarded to a research team at the University of Calgary led Dr. Daniel Muruve. Dr. Muruve is also the Chief Science Officer of Arch. The new grant will help further understand the novel mechanism of action for DPEP-1 in kidney inflammation and its impact on CKD.

Quote from Dr. Daniel Muruve:

"The cause of kidney disease is generally unknown and as a result, there are currently few treatments for acute kidney injury (AKI) or CKD. The only treatment for kidney failure, at present, is life support using dialysis or kidney transplantation. A better approach is to find new treatments for AKI and CKD that prevent kidney failure altogether. We have strong evidence that inflammation and DPEP-1 play very important roles in kidney injury and disease. We plan to study exactly how DPEP-1 contributes to kidney disease, including CKD and how to best target its function therapeutically."

About DPEP-1 and Organ Inflammation

A scientific team led by Arch scientists Dr. Donna Senger and Dr. Stephen Robbins first described a novel mechanism of action for organ inflammation in the journal Cell in August 2019. In the publication, the enzyme DPEP-1 was identified, for the first time, as a major neutrophil (white blood cell) adhesion receptor on the lung, liver and kidney endothelium. Their findings established DPEP-1 as a novel therapeutic target for diseases of these organs where inflammation plays a major role and demonstrated that DPEP-1 is the target of the Company's lead drug candidate, LSALT Peptide. The publication can be found at the following link:

"Dipeptidase-1 is an adhesion receptor for neutrophil recruitment in lungs and liver"

Subsequently in 2022, Dr. Muruve and his team explained in a publication in Science Advances how DPEP-1 regulates inflammation in the kidney. The publication can be found at the following link:

"Dipeptidase-1 governs renal inflammation during ischemia reperfusion injury"

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, liver, and kidneys via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 62,398,825 common shares outstanding.

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements, except as required by law.

The science and medical contents of this release have been approved by the Company's Chief Science Officer

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release


For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

ARCH
The Conversation (0)
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that ARCH is receiving advisory services and up to $4,000,000 in funding from the National ReseARCH Council of Canada Industrial ReseARCH Assistance Program ("NRC IRAP") to support the reseARCH and development of the LSALT peptide (Metablok) program. LSALT peptide is the Company's lead drug candidate for treating acute inflammation injury in the lungs, kidneys and liver.

The research and development funding from NRC IRAP will help support several sub-tasks needed to advance the LSALT peptide drug program. These include: dose escalation studies; costs incurred by Arch during the Canadian Treatments for COVID-19 Phase III human trial; manufacturing new drug product supply to support future non-COVID human trials; the non-COVID Phase II trials (such as a cardiac surgery associated acute kidney injury trial) to gather more human data to support future drug approval; and, additional non-clinical studies to discover potential biomarkers and to further understand the mechanism of action related to LSALT peptide.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Arch Resources Reports Fourth Quarter 2022 Results

Arch Resources Reports Fourth Quarter 2022 Results

Achieves record net income in 2022 of more than $1.3 billion , or $63.88 per diluted share
Achieves a 13-percent sequential improvement in average metallurgical segment unit cost in Q4
Declares a quarterly cash dividend of $58.0 million , or $3.11 per share
Deploys $160.2 million to repurchase 689,593 shares and settle incremental convertible debt

ARCH Resources, Inc. (NYSE: ARCH) today reported net income of $470.5 million or $23.18 per diluted share, in the fourth quarter of 2022, which included an income tax benefit of $253.3 million primarily associated with the release of a valuation allowance on the company's deferred tax assets, compared with net income of $226.6 million or $11.92 per diluted share, in the prior-year period.  ARCH had adjusted earnings before interest, taxes, depreciation, depletion, amortization, accretion on asset retirement obligations (ARO), and non-operating expenses ("adjusted EBITDA") [1] of $256.5 million in the fourth quarter of 2022, which included a $3.9 million non-cash mark-to-market gain associated with its coal-hedging activities.  This compares to $304.4 million of adjusted EBITDA in the fourth quarter of 2021, which included a $31.3 million non-cash mark-to-market gain associated with its coal-hedging activities.  Revenues totaled $859.5 million for the three months ended December 31, 2022 versus $805.7 million in the prior-year quarter.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Arch Resources to Announce Fourth Quarter 2022 Results on February 16

Arch Resources to Announce Fourth Quarter 2022 Results on February 16

ARCH Resources, Inc. (NYSE: ARCH) will discuss its fourth quarter 2022 financial results in an investor conference call on Thursday, February 16, 2023 at 10:00 a.m. Eastern time .

Arch Resources Logo (PRNewsfoto/Arch Resources, Inc.)

Interested participants may access the conference call by dialing 877-870-4263 approximately five to 10 minutes prior to the start time. For participants calling from an overseas location, please dial +1 412-317-0790.  No passcode is needed. The call will also be webcast and will be accessible via the "investor" section of the Arch website at http://investor.archrsc.com . Following the live event, a replay and an audio download will be available on the site.

Arch's fourth quarter 2022 earnings release will be distributed via PR Newswire before the market opens on February 16 and will be posted to the company's website at that time.

Arch Resources is a premier producer of high-quality metallurgical products for the global steel industry. The company operates large, modern and highly efficient mines that consistently set the industry standard for both mine safety and environmental stewardship.

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/arch-resources-to-announce-fourth-quarter-2022-results-on-february-16-301736663.html

SOURCE Arch Resources, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
DC Two Limited

DC Two Expands Beyond Data Centres & Infrastructure

DC Two Limited (ASX: DC2) (“DC Two” or the “Company”), a vertically integrated revenue generating data centre, cloud, and software business, is pleased to announce it has signed a binding conditional agreement to acquire 100% of the issued capital of managed IT and cloud services provider, Attained Group Pty Ltd (Attained).

Keep reading...Show less
nickel creek platinum stock

Nickel Creek Platinum Provides Update on Exploration Program

Nickel Creek Platinum Corp. (TSX: NCP) ("Nickel Creek" or the "Company") is pleased to announce the completion of its 2022 drilling and geophysics program at its Nickel Shaw Project in Canada'sYukon Territory with a total drilling of approximately 3,300 metres. The program included eight (8) holes with a total of approximately 2,000 metres of Prefeasibility Study ("PFS") drilling at the Wellgreen deposit which included drilling to support conversion of inferred mineral resources to indicated mineral resources and the collection of additional geotechnical and hydrogeological data including the characterization of the proposed waste dump and tailings sites. Further, the Company drilled 10 holes with a total of approximately 1,300 metres at the Arch exploration target with the objective to further define the extent of the mineralization discovered in 2021.

Keep reading...Show less
Bryah Resources

Brisbane Mining Conference

Exploring Australia For The Energy Metals Of The Future

Bryah Resources Limited (ASX: BYH, “Bryah” or “the Company”) is pleased to present its investor presentation.


Keep reading...Show less
Mt Monger Resources (ASX:MTM)

Mt. Monger Resources


Keep reading...Show less
Auric Mining

Brisbane Mining Conference Presentation

Auric Mining Limited (ASX: AWJ) (Auric or the Company) is pleased to advise Managing Director, Mark English, will be presenting at the Brisbane Mining Conference today at 10.15am (AEST) / 8:15am (AWST).

Keep reading...Show less
Firebird Metals

Firebird Grows Oakover Indicated Resource By 80% To 105.8 Million Tonnes

Firebird Metals Limited (ASX: FRB) (“Firebird” or “the Company”) is pleased to announce a significant Resource upgrade at its flagship Oakover Manganese Project, which is located 85km East of Newman in the Eastern Pilbara region of Western Australia.

Keep reading...Show less

Latest Press Releases

Related News

×